Nephrologists say they would nearly triple Xphozah use without access barriers, but Spherix chart data reveal that physicians substantially overestimate
Oncologists have moved beyond evaluating subcutaneous PD-1 inhibitors as convenient alternatives to intravenous therapy, instead incorporating them into disease-specific treatment
Early physician experience suggests TYK2 inhibition may expand oral treatment options beyond traditional positioning, with implications for future competitive dynamics
Key Takeaways A survey by Spherix Global Insights also finds that health plans and pharmacy benefit managers are using Medicare’s
Three-quarters of gastroenterologists and hepatologists report high unmet need for MASH therapies, while access to approved treatments remains limited. EXTON,
Parallel Spherix Global Insights studies reveal expanding biologic use and evolving treatment strategies have yet to fully translate into durable
Originally published in Fierce Pharma Based on feedback from doctors, Novo Nordisk’s early success with the Wegovy pill may have
Only 15% of CTD-ILD patients achieve drug-free remission, fueling interest in Bristol Myers Squibb’s zola-cel, GSK’s Benlysta, and next-generation antifibrotics.
New Spherix Global Insights research finds no clear standard of care beyond second line, creating an opportunity for novel therapies
Spherix Global Insights highlights rising enthusiasm for Priovant’s TYK2/JAK1 inhibitor alongside continued dissatisfaction with current treatment approaches in dermatomyositis and
Despite a more flexible administration profile, Foundayo generated lower first-month prescribing rates than the Wegovy Pill among both primary care
Analysis of 187 audited patient charts reveals persistent operational barriers remain common for patients with large B-cell lymphoma (LBCL), reinforcing
